 |
|
|
| |
Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study: The NEED study
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
W.-W. Su1, C.-W. Hsu2, C.-M. Lee3, C.-Y. Peng4, W.-L. Chuang5, J.-H. Kao6, R.-N. Chien7, H.-C. Chu8,
Y.-H. Huang9, Y.-F. Liaw2
1Changhua Christian Hospital, Changhua, Taiwan, 2Chang Gung Memorial Hospital, Chang Gung
University College of Medicine, Taipei, 3Chang Gung Memorial Hospital, Kaohsiung, 4China Medical
University Hospital, Taichung, 5Kaohsiung Medical University Hospital, Kaohsiung, 6National Taiwan
University Hospital, Taipei, 7Chang Gung Memorial Hospital, Keelung, 8Tri-Service General Hospital,
9Taipei Veterans General Hospital, Taipei, Taiwan
from Jules: yesterday I distributed to the NATAP listserve the EASL 2014 oral presentation of
Pegasys+entecavir in HBV study presented by Brouwer et al, their study had different patient population
than the Chinese NEED Study, perhaps different genotypes, and different study design. Here is the
oral presentation of the other study. The study design appears different: 6 weeks only of the antiviral while patients in the
other study received 48 weeks of entecavir in combination with 48 weeks entecavir, with nonresponders
extending to 72 weeks. And then in this study the HIV-DNA response we were provided was after 4 weeks.
|
| |
|
|
|
|
|
